logo

BNGO

Bionano Genomics·NASDAQ
--
--(--)
--
--(--)
0.08 / 10
Underperform

BNGO's fundamental score is subpar (0.1/10), marked by negative net income-to-revenue (-89.8%) and weak asset utilization (Current assets turnover 0.466). Revenue growth is contracting (-9.1% YoY), and cash flow from operations is negative (-59.2%). Only Net profit margin to revenue ratio shows a positive read (100%), but historical back-tests indicate limited upside. These factors collectively suggest constrained potential and subdued fundamental underpinnings.

Fundamental(0.08)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value1.56
Score3/3
Weight-529.88%
1M Return3.41%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight211.92%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value-9.09
Score1/3
Weight290.34%
1M Return-2.56%
Net cash flow from operating activities / Operating revenue (%)
Value-59.20
Score1/3
Weight230.97%
1M Return-2.03%
Net income-Revenue
Value-0.17
Score1/3
Weight94.57%
1M Return-0.69%
Net profit margin (%)
Value-89.81
Score2/3
Weight-127.58%
1M Return0.90%
Current assets turnover ratio
Value0.47
Score2/3
Weight-37.27%
1M Return0.26%
EBIT / Total operating revenue (%)
Value-92.62
Score2/3
Weight-158.75%
1M Return1.12%
Asset-MV
Value-0.50
Score0/3
Weight278.41%
1M Return-6.43%
Net profit / Total operating revenue (%)
Value-89.81
Score2/3
Weight-152.72%
1M Return1.07%
Is BNGO undervalued or overvalued?
  • BNGO scores 0.08/10 on fundamentals and holds a Premium valuation at present. Backed by its -43.35% ROE, -134.36% net margin, -0.16 P/E ratio, 0.23 P/B ratio, and 90.73% earnings growth, these metrics solidify its Underperform investment rating.